ATE303397T1 - 9-alpha-substituierte estratriene als selektiv wirksame estrogene - Google Patents

9-alpha-substituierte estratriene als selektiv wirksame estrogene

Info

Publication number
ATE303397T1
ATE303397T1 AT03757065T AT03757065T ATE303397T1 AT E303397 T1 ATE303397 T1 AT E303397T1 AT 03757065 T AT03757065 T AT 03757065T AT 03757065 T AT03757065 T AT 03757065T AT E303397 T1 ATE303397 T1 AT E303397T1
Authority
AT
Austria
Prior art keywords
alpha
selectively effective
substituted estratrienes
estrogens
effective estrogens
Prior art date
Application number
AT03757065T
Other languages
German (de)
English (en)
Inventor
Dirk Kosemund
Gerd Mueller
Alexander Hillisch
Karl-Heinrich Fritzemeier
Peter Muhn
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of ATE303397T1 publication Critical patent/ATE303397T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03757065T 2002-06-11 2003-06-11 9-alpha-substituierte estratriene als selektiv wirksame estrogene ATE303397T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
PCT/EP2003/006172 WO2003104253A2 (de) 2002-06-11 2003-06-11 9-alpha-substituierte estratriene als selektiv wirksame estrogene

Publications (1)

Publication Number Publication Date
ATE303397T1 true ATE303397T1 (de) 2005-09-15

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03757065T ATE303397T1 (de) 2002-06-11 2003-06-11 9-alpha-substituierte estratriene als selektiv wirksame estrogene

Country Status (28)

Country Link
EP (1) EP1517914B1 (enExample)
JP (1) JP4615998B2 (enExample)
KR (1) KR101006612B1 (enExample)
CN (1) CN1293090C (enExample)
AR (1) AR040188A1 (enExample)
AT (1) ATE303397T1 (enExample)
AU (1) AU2003242683B9 (enExample)
BR (1) BR0312140A (enExample)
CA (1) CA2486495C (enExample)
CR (1) CR10289A (enExample)
CU (1) CU23414B7 (enExample)
DE (2) DE10226326A1 (enExample)
DK (1) DK1517914T3 (enExample)
EA (1) EA008442B1 (enExample)
EC (1) ECSP055530A (enExample)
ES (1) ES2248770T3 (enExample)
HR (1) HRP20050009B1 (enExample)
IL (1) IL165321A (enExample)
MX (1) MXPA04012491A (enExample)
NO (1) NO329563B1 (enExample)
PE (1) PE20040613A1 (enExample)
PL (1) PL209910B1 (enExample)
RS (1) RS50878B (enExample)
TW (1) TWI286140B (enExample)
UA (1) UA78062C2 (enExample)
UY (1) UY27844A1 (enExample)
WO (1) WO2003104253A2 (enExample)
ZA (1) ZA200500217B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP1689410B1 (en) * 2003-11-26 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2252261A2 (en) * 2008-02-13 2010-11-24 Bayer Schering Pharma Aktiengesellschaft Drug delivery system with stabilising effect
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2010057594A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
EP3185881B1 (en) 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CA3109978A1 (en) * 2018-09-07 2020-03-12 Trustees Of Dartmouth College C19 scaffolds and steroids and methods of use and manufacture thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
EP1226155B1 (de) * 1999-11-02 2007-05-02 Bayer Schering Pharma AG 18-nor-steroide als selektiv wirksame estrogene
AU5834101A (en) * 2000-04-12 2001-10-23 Schering Ag 8ss-hydrocarbyl-substituted estratrienes for use as selective estrogens

Also Published As

Publication number Publication date
CA2486495C (en) 2011-04-19
TWI286140B (en) 2007-09-01
PL373090A1 (en) 2005-08-08
HRP20050009B1 (hr) 2013-07-31
ES2248770T3 (es) 2006-03-16
AU2003242683A1 (en) 2003-12-22
NO20050127L (no) 2005-03-11
WO2003104253A2 (de) 2003-12-18
ZA200500217B (en) 2006-03-29
DE10226326A1 (de) 2004-01-15
CN1659181A (zh) 2005-08-24
JP4615998B2 (ja) 2011-01-19
CN1293090C (zh) 2007-01-03
KR20050009745A (ko) 2005-01-25
DK1517914T3 (da) 2006-01-16
AU2003242683B2 (en) 2009-07-02
NO20050127D0 (no) 2005-01-10
NO329563B1 (no) 2010-11-15
ECSP055530A (es) 2005-03-10
HRP20050009A2 (en) 2005-04-30
PE20040613A1 (es) 2004-12-01
KR101006612B1 (ko) 2011-01-10
HK1081203A1 (en) 2006-05-12
PL209910B1 (pl) 2011-11-30
TW200407331A (en) 2004-05-16
UA78062C2 (en) 2007-02-15
IL165321A (en) 2009-08-03
CR10289A (es) 2008-11-26
EP1517914A2 (de) 2005-03-30
CU23414B7 (es) 2009-09-08
UY27844A1 (es) 2003-12-31
CA2486495A1 (en) 2003-12-18
DE50301116D1 (de) 2005-10-06
MXPA04012491A (es) 2005-06-08
RS50878B (sr) 2010-08-31
RS107004A (sr) 2006-10-27
EA008442B1 (ru) 2007-06-29
AU2003242683B9 (en) 2009-08-27
AR040188A1 (es) 2005-03-16
JP2005533053A (ja) 2005-11-04
EP1517914B1 (de) 2005-08-31
BR0312140A (pt) 2005-04-05
WO2003104253A3 (de) 2004-09-16
EA200401544A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
ATE316978T1 (de) Ent-steroide als selektiv wirksame estrogene
DE60327587D1 (de) Hohlkammerplatte
NL1026490A1 (nl) Instructiesetextensie onder gebruikmaking van 3-byte escape opcode.
DE60108945D1 (de) Berührungsempfindliche Tafel
ITMI20020148A1 (it) Nuovi corticosteroidi
DE112004000857D2 (de) Eisen-Chrom-Aluminium-Legierung
ATE313553T1 (de) 16-hydroxyestratriene als selektiv wirksame estrogene
ATE303397T1 (de) 9-alpha-substituierte estratriene als selektiv wirksame estrogene
ZA200507351B (en) Steroid spirolactonization
DE602004010971D1 (de) Verstärktes Bauteil
NO20004174L (no) Anordning ved stomikrage
EP1625143A4 (en) ÖSTRATRIENDERIVATE
DE60328179D1 (de) Adressenregistern
DE60224982D1 (de) Androgenische 7-substituierte 11-halogenierte steroide
GB2390443B (en) Application registers
DE60312112D1 (de) Verstärktes Bauelement
FR2852200B1 (fr) Panneau de chalut
SI1272504T1 (sl) 8beta-hidrokarbilno substituirani estratrieni kotestrogeni s selektivnim učinkom
FR2857607B1 (fr) Tunnel de decontamination
AT503225A3 (de) Holzbautafel
ATA80212002A (de) Plattenaufteilsäge
ATE294812T1 (de) 16alpha-methyl oder ethyl substituierte oestrogene
DE50307449D1 (de) Ablaufgarnitur
DE50310827D1 (de) Schaltklappenvorrichtung
IL165321A0 (en) 9-alpha-substituted estratrienes as selectively active estrogen